ShareValue.ai

ShareValue scores for KVUE: Valuation 48, Quality 53, Growth 51, Health 51.

Kenvue Inc. logo

KVUE
NYSE

Kenvue Inc.

$19.13(+0.90%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 16%
Valuation
48
Fair Value
Price vs Value
Quality
53
Moderate
Business Strength
Growth
51
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
66
Bullish
Price Trend

Company Details

About

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026